Healthcare Business Recap: GNC Holdings Beats Wall Street, Vivus Drops on Rumors
Brean Murray issues a Buy rating on Celsion (NASDAQ:CLSN) along with positive comments on the strength of promising data it expects to see released on Celsion’s ThermoDox treatment later this year. Shares were up substantially premarket. Additionally, Brean set a price target of $7 for the company, marking a 267% upside potential
Investing Insights: Mylan Laboratories Inc. Fourth Quarter Earnings Sneak Peek.
The Q4 EPS of $1.16 for Five Star Quality Care (AMEX:FVE) might not fit consensus of $0.02. Revenue of $332.8M in-line is projected.
GNC Holdings (NYSE:GNC) beats the estimates of analysts on both its top-line and bottom-line results for Q4, causing its shares to rise premarket. Firm Guidance from the company was also strong, with a forecast for FY12 of EPS at $1.82 and revenue of $2.28B vs. consensus of $1.73 and $2.25B, respectively.
Shares of Vivus (NASDAQ:VVUS) fell sharply in the afternoon after being in the green earlier in the day. The fly in the ointment could be rumors that the FDA might require a large cardiovascular safety study of Qnexa before approving it.
Healthways’s (NASDAQ:HWAY) Q4 misses estimates across the board. A steep drop in the health-care provider’s market capitalization was too much for the Y/Y marginal rise in net profits to outweigh. These factors forced Healthways to write down some of its value.
Earnings Report: Medtronic Inc. Third Quarter Earnings Sneak Peek.
To contact the reporter on this story: Mark Lawson at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com